Stock CTXR CITIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 29/06/2024 am IST 		5-day change 1st Jan Change
0.5837 USD -8.54% Intraday chart for Citius Pharmaceuticals, Inc. -8.87% -22.84%
21/05 Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution CI
14/05 Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI

Business Summary

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Number of employees: 22

Managers

Managers TitleAgeSince
Leonard Mazur CEO
 Chief Executive Officer 79 01/13/01
Jaime Bartushak DFI
 Director of Finance/CFO 57 27/17/27
Preeti Singh CTO
 Chief Tech/Sci/R&D Officer - 01/22/01
Myron Czuczman CTO
 Chief Tech/Sci/R&D Officer 65 14/20/14
Alan Lader CTO
 Chief Tech/Sci/R&D Officer - 01/16/01
Gary Talarico COO
 Chief Operating Officer 69 01/16/01
Myron Holubiak BRD
 Director/Board Member 77 01/15/01
Ilanit Allen IRC
 Investor Relations Contact - 17/21/17
Catherine Kessler LAW
 General Counsel - 10/22/10
Paul Sowyrda PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Myron Holubiak BRD
 Director/Board Member 77 01/15/01
Dennis McGrath BRD
 Director/Board Member 67 07/23/07
Leonard Mazur CEO
 Chief Executive Officer 79 01/13/01
Carol Webb BRD
 Director/Board Member 78 01/16/01
Suren Dutia BRD
 Director/Board Member 82 01/15/01
Eugene Holuka BRD
 Director/Board Member 65 01/16/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 180,673,355 168,365,416 ( 93.19 %) 0 93.19 %

Shareholders

NameEquities%Valuation
Leonard Mazur
5.676 %
10,255,343 5.676 % 7 M $
BlackRock Advisors LLC
4.645 %
8,392,359 4.645 % 6 M $
Vanguard Fiduciary Trust Co.
3.877 %
7,005,119 3.877 % 5 M $
Geode Capital Management LLC
1.630 %
2,945,494 1.630 % 2 M $
STATE STREET CORPORATION
1.223 %
2,209,564 1.223 % 2 M $
Myron Holubiak
1.103 %
1,992,243 1.103 % 1 M $
Northern Trust Investments, Inc.(Investment Management)
0.5674 %
1,025,097 0.5674 % 714 493 $
Osaic Wealth, Inc.
0.5363 %
969,036 0.5363 % 675 418 $
Teachers Advisors LLC
0.2682 %
484,649 0.2682 % 337 800 $
Charles Schwab Investment Management, Inc.
0.1976 %
356,994 0.1976 % 248 825 $

Company contact information

Citius Pharmaceuticals, Inc.

11 Commerce Drive 1st floor

07016, Cranford

+908 967 6677

http://www.citiuspharma.com
address Citius Pharmaceuticals, Inc.(CTXR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6382 USD
Average target price
4 USD
Spread / Average Target
+526.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CITIUS PHARMACEUTICALS, INC. Stock Citius Pharmaceuticals, Inc.
-22.84% 12Cr
LONZA GROUP AG Stock Lonza Group AG
+38.65% 3.91TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 3.88TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 3.12TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 2.59TCr
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 2.58TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 1.41TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 1.31TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 1.13TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.61% 1.07TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CTXR Stock
  4. Company Citius Pharmaceuticals, Inc.